Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited [TSE:4502] (「Takeda」) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and ......
